eligibility_summary
Adults 18–70 with pathologically confirmed unresectable locally advanced/metastatic NSCLC, ≥1 measurable lesion (RECIST v1.1), ECOG 0–1, able to consent and comply. Excludes active/symptomatic brain mets, other prior malignancy, symptomatic ascites, uncontrolled or moderate+ pleural/pericardial effusions, anti-cancer therapy within 4 weeks, uncontrolled tumor pain, severe cardiovascular/cerebrovascular disease.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: Phase Ib/II, single-arm study in advanced/metastatic NSCLC testing three agents: 1) Adebrelimab (SHR‑1316): a humanized monoclonal antibody immune‑checkpoint inhibitor targeting PD‑L1, it blocks PD‑L1 interaction with PD‑1/CD80 to restore cytotoxic T‑cell activation and antitumor immunity. 2) SHR‑A2102: an investigational anticancer agent given IV, the registry does not specify its drug class or precise mechanism. 3) SHR‑8068: an investigational IV immunotherapy, the registry does not specify its target/mechanism. Targeted cells/pathways: PD‑L1 on tumor and immune cells (reinvigorating T‑cell responses in the tumor microenvironment). The combination is intended to augment antitumor immunity via PD‑L1 blockade plus additional, unspecified immune/tumor‑cell pathways.